Try Behavioral Therapy First When Treating Overactive Bladder in Men
New study results reinforce OAB guidelines recommending behavioral therapy as first-line treatment.
Overactive Bladder/Enuresis
NDA Submitted for Vibegron for Overactive Bladder Treatment
Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The NDA submission includes data from an extensive clinical development program involving over 4000 patients with…
OTC Urethral Support Device Now Available to Treat Stress Urinary Incontinence
An over-the-counter device to treat stress urinary incontinence (SUI) in women has been made available by Rinovum Women’s Health.
AUA Updates Overactive Bladder Guideline
Updated OAB guideline now says clinicians may consider combination therapy with an antimuscarinic and beta3-andrenoceptor agonist for patients refractory to monotherapy with either of those medications.
Solabegron Meets Primary Endpoint in Overactive Bladder Study
Velicept Therapeutics announced that solabegron met the primary endpoint in the phase 2b VEL-2002 study that evaluated patients with overactive bladder (OAB).
Vibegron Cuts Daily Urge Urinary Incontinence Episodes, Micturitions in OAB Study
Urovant Sciences announced topline data from the phase 3 EMPOWUR trial which evaluated vibegron in adult patients with symptoms of overactive bladder.
Some Nocturia Cases May Be Eased By Restricting Salt Intake
Decreasing salt intake may benefit patients with nocturia who are heavy salt users, according to a new study published in Neurourology and Urodynamics. In a prospective study, Tomohiro Matsuo, MD, and colleagues from Nagasaki University Graduate School of Biomedical Sciences in Nagasaki, Japan, analyzed changes in lower urinary tract symptoms in 321 patients with nocturia…
Overactive Bladder Linked to Prostate Cancer ADT
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
OAB Symptoms Eased With Intravesical Botulinum Toxin
In a small trial, patients receiving 300 U and 500 U of intravesical abobotulinumtoxin A experienced reductions in nocturia episodes at 12 and 24 weeks.
Nocturia, Overactive Bladder Improved With PTNS
In a study, percutaneous tibial nerve stimulation reduced nocturia episodes by 0.8 on average.
Next post in Overactive Bladder (OAB)
